Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Office Of Drug Safety Director-Designate Is ODE III Deputy Raczkowski

Executive Summary

FDA Office of Drug Safety Director-designate Victor Raczkowski, MD, brings hands-on experience with the application of risk-management techniques from the review of GlaxoSmithKline's Lotronex

You may also be interested in...



FDA Office Of Drug Safety In Transition; Director Raczkowski Joins Cephalon

Former FDA Office of Drug Safety Director Victor Raczkowski, MD, is joining Cephalon as VP-regulatory affairs

FDA Office Of Drug Safety In Transition; Director Raczkowski Joins Cephalon

Former FDA Office of Drug Safety Director Victor Raczkowski, MD, is joining Cephalon as VP-regulatory affairs

FDA GI Division Director Justice Is Returning To FDA From Genentech

Genentech Senior Clinical Scientist Robert Justice, MD, is returning to FDA as director of the Division of Gastrointestinal & Coagulation Drug Products in September

Related Content

UsernamePublicRestriction

Register

PS078529

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel